To achieve its objective to become a first-class biopharmaceutical enterprise in China, the Company will continue to seek to secure its market position by enhancing existing products, introducing new products to meet customer demand, delivering quality products to customers in a timely manner and maintaining the already established industry reputation.
"We are very pleased to be operating in a more regulated market for plasma-based products after recent reforms launched by the government," said Mr. Stanley Wong, CEO of China Biologic Products. "We are going to continue our efforts to gain more market share and improve our product mix."
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiary Shandong Taibang, is currently the only plasma-based biopharmaceutical company approved by the government of Shandong Province, the second largest province with a population of 93 million. The company is engaged primarily in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Plasma-based Human Albumin is used mainly to increase blood volume while Immunoglobulin is used for disease prevention and treatment.
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to
the business of the Company and its subsidiary companies. All statements,
other than statements of historical fact included herein are
"forward-looking statements" including statements regarding the general
ability of the Company to achieve its commercial objectives; the business
|SOURCE China Biologic Products, Inc.|
Copyright©2008 PR Newswire.
All rights reserved